Edelweiss is bullish on Max India has recommended buy rating on the stock with a target price of Rs 175 in its research report dated February 14, 2017.
Edelweiss' research report on Max India
We believe Max is a compelling bet on the tertiary care opportunity in the NCR market, which could have upsides from investments in health insurance. Maintain ’BUY’ with TP of INR 175.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.